AAM Urges Trump Not To Destabilize Supply Chain
Warns ‘Buy American’ Changes Could Hinder COVID-19 Pandemic Response
The AAM has warned the Trump administration that ‘Buy American’ requirements on medicines could limit patient access to affordable medicines and increase the risk of drug shortages during the coronavirus pandemic.
You may also be interested in...
In an attempt to strengthen the US generic drug supply chain and reduce dependence on certain countries for supply, the AAM has proposed a policy framework “blueprint” that requires government purchasing commitments in exchange for industry manufacturing expansion.
Manufacturers, insurers, pharmacies and PBMs are united in trying to assure ongoing access to medicines amid the COVID-19 outbreak. Will making common cause in a national emergency mean a more cooperative approach to addressing US drug pricing concerns when normalcy returns?
The AAM has outlined a set of principles that it says will help protect patient access to generics and biosimilars and aid in efforts to diversify the supply chain to help mitigate future crises. The association said it would work with policymakers and other stakeholders to formulate policies to address concerns that the coronavirus pandemic has raised.